Medical Condition News

RSS

Healthy food choices found to be key in reducing heart disease risk

A new study that followed almost 200,000 people for several decades has found that when it comes to heart health, the quality of food consumed matters as much as following a low-carbohydrate or low-fat diet.

1 Jun 2025

Treatment switching guided by liquid biopsy results improves outcomes in advanced breast cancer

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.

1 Jun 2025

Linoleic acid may help to lower risks for heart disease and type 2 diabetes

New research that used blood markers to measure linoleic acid levels and their relation to cardiometabolic risk adds evidence that this omega-6 fatty acid may help to lower risks for heart disease and type 2 diabetes.

1 Jun 2025

Obesity associated with anxiety and cognitive impairment in mice

With rates of obesity and anxiety both on the rise-especially among younger Americans-new research suggests that the two conditions may be connected through interactions between the gut and the brain.

1 Jun 2025

Anti-inflammatory diet linked to longer survival in colon cancer patients

Patients with colon cancer who consumed an anti-inflammatory diet during a phase 3 clinical trial showed longer overall survival post-treatment compared to those on a proinflammatory diet, according to a Dana-Farber Cancer Institute analysis.

1 Jun 2025

Adding immunotherapy to chemotherapy after surgery improves survival in colon cancer

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.

1 Jun 2025

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC).

1 Jun 2025

Dual-target CAR T cell therapy shrinks tumors in aggressive brain cancer

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.

1 Jun 2025

Combination treatment extends progression-free survival in advanced skin cancer

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.

1 Jun 2025

Gene expression study reveals clues to asbestos-linked mesothelioma

Gene expression leading to alterations in the DNA caused by asbestos exposure may explain the development of Malignant Pleural Mesothelioma (MPM), a rare and aggressive cancer.

31 May 2025

New microfluidic device brings affordable kidney testing to the point of care

Chronic kidney disease (CKD) affects over 800 million people globally and is often diagnosed too late for effective intervention.

31 May 2025

Leading health organizations release guidance on nutrition support for GLP-1 obesity therapies

Four leading organizations in lifestyle medicine, obesity medicine, and nutrition-the American College of Lifestyle Medicine (ACLM), the American Society for Nutrition (ASN), the Obesity Medicine Association (OMA), and The Obesity Society (TOS)-have jointly released a clinical advisory titled "Nutritional Priorities to Support GLP-1 Therapy for Obesity."

31 May 2025

Cancer survivor population in the US expected to surpass 22 million by 2035

The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025 and projected to exceed 22 million by 2035, according to a new report, Cancer Treatment and Survivorship Statistics, 2025, led by the American Cancer Society (ACS).

31 May 2025

Universal CAR T cell therapy shows promise for aggressive T cell cancers

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led by researchers at Washington University School of Medicine in St. Louis.

31 May 2025

Study could change the definition of wound closure in diabetes care

In patients with diabetic foot ulcers that looked healed and met the current definition of a closed wound, closed ulcers with functionally defective skin that lost more body water were likely to re-open, according to a new National Institutes of Health (NIH) Diabetic Foot Consortium study, led by researchers at the University of Pittsburgh and published today in Diabetes Care.

31 May 2025

Men with common genetic variant twice as likely to develop dementia

New research has found that men who carry a common genetic variant are twice as likely to develop dementia in their lifetime compared to women.

31 May 2025

Structural racism and social defeat may drive psychosis in marginalized youth

Prevailing theories about why young people experience psychotic breaks at a young age rely on individual factors like exposure to child abuse, school bullying, or drugs.

30 May 2025

Upper gastrointestinal involvement is common in Egyptian patients with ulcerative colitis

This study investigates upper gastrointestinal tract (UGIT) involvement in patients with ulcerative colitis (UC), a condition traditionally considered limited to the colon.

30 May 2025

Triplet therapy significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the Phase III BREAKWATER trial led by researchers from The University of Texas MD Anderson Cancer Center.

30 May 2025

Cross-cultural analysis reveals differences in socio-cognitive abilities of autistic and non-autistic adults

Emerging theories suggest that communication challenges arise from differing perspectives between autistic and non-autistic partners rather than individual socio-cognitive deficits.

30 May 2025